Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers in our Department will lead a new collaborative initiative for Spinal Muscular Atrophy (SMA) research in the UK over the next three years. The programme is funded by the SMA Trust.

SMA is caused by a faulty gene that affects nerve cells needed to control the muscles we use for moving, swallowing and breathing. 1 in 40 of us is a carrier and in the most severe cases (50% of those affected), children rarely live beyond 2 years old – making SMA the leading genetic cause of death in babies and toddlers.

The main aims of the consortium are to further develop existing drug targets and identify new neuroprotective therapies to maintain nerve function throughout the lives of people living with SMA, and to identify improved ways of delivering treatments in order to maximise benefit throughout the body.

Read more on the University of Oxford website...

Similar stories

John Jacob wins clinical academic research partnership for brain cancer project

The Medical Research Council awarded Dr John Jacob upwards of £200,000 to fund a project on brain cancer modelling.

Newborn brain scans clarify how some diseases develop

Newborn brain scans from the Developing Human Connectome Project are now available online in large-scale open-source project, clarifying how some diseases develop.

New consortium to uncover mechanisms of neuropathic pain

Professor David Bennett is leading a new national research consortium to investigate neuropathic pain.

NDCN Thomas Willis Day Prize Winners

Our annual Thomas Willis Day celebrates the work of our Department over the previous year.